April 3, 2023 Following success of stage 2 and stage 3 clinical trials with antiCinterleukin-6 receptor tocilizumab61,62 and its own approval, additional, industry- or investigator-sponsored trials, where VCRC and EUVAS members are participating, are in advancement using the goals of improving therapeutic choices for sufferers with insufficient intolerance or response to tocilizumab
March 17, 2022 Between-group variations in count ideals for each region were tested for statistical significance by using ANOVA, with treatment condition (i
November 8, 2021 Along the HIV genome, diversity patterns and compositions of nucleotides and proteins were similar across different groups highly, cRFs and subtypes